title: Understanding new cholesterol-lowering agents.
authors.affiliation: Amanda Jo Shigle is a PharmD candidate at Ohio Northern University in Ada, Ohio. Dan Sheridan is a medication safety pharmacist at OhioHealth Marion General Hospital in Marion, Ohio.
authors.forename: Amanda Jo
authors.initials: AJ
authors.lastname: Shigle
authors.forename: Dan
authors.initials: D
authors.lastname: Sheridan
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002983:Clinical Competence; D017277:Drug Approval; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000451:nursing*; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; C577155:evolocumab; C571059:alirocumab